BiotechTube

Pumitamig + Folfox + Capox + Nivolumab

Phase 2/3Recruiting
0 views this week 0 watching⚡ Active
Interest: 45/100
45
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Conditions

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Trial Timeline

Mar 31, 2026 → Sep 11, 2032

NCT ID
NCT07221149

About Pumitamig + Folfox + Capox + Nivolumab

Pumitamig + Folfox + Capox + Nivolumab is a phase 2/3 stage product being developed by Bristol Myers Squibb for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07221149. Target conditions include Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.

What happened to similar drugs?

1 of 4 similar drugs in Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma were approved

Approved (1) Terminated (1) Active (2)
✅Nivolumab + RelatlimabBristol Myers SquibbApproved
🔄Acalabrutinib + Rituximab + ChlorambucilAstraZenecaPhase 3
🔄Surovatamig + R-CHOP + R-CVP + BRAstraZenecaPhase 3
❌Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
15
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07221149Phase 2/3Recruiting

Competing Products

15 competing products in Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusionAbbViePhase 2
35
Onureg + VenetoclaxAbbViePhase 1/2
36
Acalabrutinib + Rituximab + ChlorambucilAstraZenecaPhase 3
44
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatinAstraZenecaPhase 2
27
Surovatamig + R-CHOP + R-CVP + BRAstraZenecaPhase 3
47
MK-3475 + Lenvatinib + Carboplatin + PaclitaxelMerckPhase 2
42
UFOX + Cetuximab + FOLFOX4 + CetuximabMerckPhase 2
35
Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + VincristineRochePhase 2
35
Rituximab + ACVBP regimen plus PegfilgrastimAmgenPhase 2
35
Idelalisib + Nab-paclitaxel + mFOLFOX6Gilead SciencesPhase 1
21
PF-08634404 + Chemotherapy + NivolumabPfizerPhase 2/3
45
Nivolumab + RelatlimabBristol Myers SquibbApproved
50
Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3
32
Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + GemcitabineBristol Myers SquibbPhase 2
35
Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOXBristol Myers SquibbPhase 2/3
45